AUTHORS
Xuan Zhou, PhD, Daohua Ning2, Lisi Huang, MD,PhD3, Feiheng Chen4, Qiang WANG, MD5, Xiaoli Liu, MD6, Na Xu7
AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Anshan Central Hospital,Liaoning Provincial, Anshan, China
3 Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
4 The First Affiliated Hospital of Shantou University Medical College, Shantou, China
5 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
ABSTRACT
Introduction: Myelofibrosis (MF) is a Philadelphia chromosome–negative myeloproliferative neoplasm. Ruxolitinib, the current standard of care, confers substantial clinical benefit; however, resistance or intolerance develops in a significant proportion of patients. Selinexor, a first-in-class selective inhibitor of XPO-1–mediated nuclear export, has demonstrated preclinical synergy with JAK inhibition. Real-world evidence on the selinexor–ruxolitinib combination in patients with prior ruxolitinib exposure remains limited. This multicenter retrospective study aimed to evaluate the efficacy and safety of this combination in a real-world Chinese MF cohort.
Methods: This multicenter, retrospective study included 67 patients with MF treated with selinexor plus ruxolitinib. Eligible patients had PMF, post-PV MF, or post-ET MF per WHO 2016 criteria. Selinexor was administered at 20–60 mg once weekly, in combination with ruxolitinib (mostly 10 mg twice daily). Intolerance to prior ruxolitinib was defined as dose reduction or discontinuation due to grade ≥3 cytopenias or other adverse events per investigator assessment. Responses were assessed per IWG-MRT criteria, including anemia response (hemoglobin increase ≥20 g/L), spleen response (palpation reduction ≥50% or SVR35), and symptom response (TSS50). The primary endpoint was composite spleen response rate; secondary endpoints included anemia response, TSS50, treatment duration, and safety.
Results: The cohort was advanced-stage and heavily pretreated: median age 56 years (range, 27-76); 47.8% male. PMF was the predominant diagnosis (86.6%), followed by ET-MF (9.0%) and PV-MF (4.5%). DIPSS risk categories included intermediate-2 (14.9%) and high-risk (7.5%).Among the 31 patients with available mutation data, driver mutations comprised JAK2_V617F in 17 cases (54.8%), CALR in 8 cases (25.8%), MPL in 3 cases (9.7%), and triple-negative in 3 cases (9.7%). High-risk mutations (HRM) (ASXL1, SRSF2, EZH2, IDH1/2) were present in 31.3%, ASXL1 most common (23.9%). Median baseline hemoglobin was 86 g/L (IQR, 73-99); 83.6% had palpable splenomegaly; 25.0% were transfusion-dependent. The median duration of prior ruxolitinib therapy was 12.0 months (IQR, 9.0-24.0). Selinexor starting doses were 20 mg (43.3%), 40 mg (28.4%), and 60 mg (4.5%); doses were individualized per treating physician.With a median follow-up of 4.2 months (range, 0.5-13.8), among evaluable patients at Cycle 3 (n=12), the SVR35 rate was 50.0% (6/12); by palpation criteria, spleen response was achieved in 18.2% (2/11). The composite spleen response rate (palpation or imaging) was 35.3% (6/17). TSS50 was achieved in 100% (12/12) of evaluable patients at Cycle 3. Anemia response at Cycle 3 was 20.0% (6/30); among non-transfusion--dependent patients, anemia improvement occurred in 27.0% (10/37), while among transfusion-dependent patients, 53.3% (8/15) achieved sustained transfusion independence. The clinical improvement (CI) rate per IWG-MRT criteria was 46.0% (23/50) among patients with at least one evaluable assessment. In an exploratory biomarker analysis, peripheral monocyte percentage decreased from 10.5% at baseline to 8.6% post-treatment (n=21 paired samples; P=0.37), with a reduction observed in 66.7% (14/21) of patients. In subgroup analyses, HRM-positive patients demonstrated a numerically higher spleen response rate (50.0% vs 22.2%) but a shorter median duration of treatment (DOT; 2.3 vs 2.8 months) compared with HRM-negative patients, suggesting retained activity despite reduced durability. The median DOT for the overall cohort was 2.8 months (IQR, 1.7--5.5). Eleven patients (16.4%) required dose adjustment or treatment discontinuation, primarily due to infection, disease progression, or non-compliance. Progression to accelerated phase occurred in 10.4% (7/67); 4 deaths (6.0%) were reported, none treatment-related.
Conclusion: In this real-world Chinese cohort of patients with MF resistant or intolerant to prior ruxolitinib, adding selinexor demonstrated clinically meaningful efficacy, with an SVR35 of 50% and TSS50 of 100% at Cycle 3, and anemia benefits including transfusion independence in over half of transfusion-dependent patients. HRM-positive patients, typically refractory to JAK inhibitor monotherapy, showed preserved spleen responses, suggesting selinexor may be an effective add-back strategy in this high-risk subgroup. The safety profile was manageable and consistent with known toxicities.
DISCLOSURES
Xuan Zhou, PhD: No relevant conflicts of interest to declare.